Inspire Medical Systems Inc

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inspire Medical Systems achieves first profitable quarter, eyes international growth

Inspire Medical Systems reported a strong performance in Q4 2022, achieving its first profitable quarter and significant revenue growth. The company's focus on enhancing patient outcomes, expanding internationally, and optimizing operational efficiency positions it for continued success.
While challenges with the supply chain were addressed, the company needs to remain vigilant in managing disruptions and addressing analyst concerns to ensure sustained growth. Opportunities in product demand, market expansion, and operational enhancements offer avenues for further development.
Overall, Inspire Medical Systems' strategic initiatives, strong financial performance, and commitment to innovation indicate a positive outlook for future growth and market expansion. The company's focus on driving utilization, improving patient outcomes, and maintaining operational efficiency bodes well for its long-term success.

Inspire Medical Systems Inc reports stellar Q1 performance and eyes global growth opportunities

Inspire Medical Systems Inc delivered robust financial results in Q1 2023, driven by revenue growth and international expansion.
The company's strategic focus on innovation, customer engagement, and therapy adoption positions it well for future success.
Challenges in competition, operational efficiency, and market dynamics require careful navigation, but opportunities for growth and innovation abound.
Overall, Inspire's performance reflects a company poised for continued expansion and impact in the medical technology sector.

Inspire Medical Systems reports robust Q2 growth and eyes global expansion

Inspire Medical Systems delivered strong financial performance in Q2, with revenue growth and margin improvement.
The company's strategic focus on expanding globally, enhancing operational efficiency, and product innovation positions it for future success.
While facing challenges in managing expenses and market mix, Inspire Medical Systems is well-positioned to capitalize on growth opportunities.
Overall, the company's performance, strengths, and strategic initiatives indicate a positive outlook for future growth and market expansion.

Inspire Medical Systems achieves record patient milestone and revenue growth

Inspire Medical Systems reported strong performance in Q3 2023, with notable revenue growth and patient milestones.
Despite challenges with prior authorizations and EU MDR approval delays, the company remains focused on growth and stakeholder value.
Opportunities for expansion with payers and new programs signal a positive outlook for future growth and market reach.
Efforts to streamline processes, educate centers, and drive efficiencies position the company for continued success in the sleep apnea treatment market.

Inspire Medical Systems posts robust Q4 results, eyes global expansion

Inspire Medical Systems reported strong Q4 performance, focusing on growth, profitability, and patient outcomes.
Challenges include market competition, revenue declines in certain regions, and securing reimbursements.
Opportunities lie in expanding utilization rates, market growth in Europe and Asia, and collaborations for increased patient flow.

Inspire Medical Systems Inc reports robust Q1 performance and growth outlook

Inspire Medical Systems Inc's Q1 2024 performance reflects strong revenue growth, improved net loss metrics, and a positive outlook for profitability and revenue expansion in 2024.
The company's strengths lie in its patient-centric approach, innovative product pipeline, and strategic growth initiatives, while challenges include financial performance, competitive landscape, and market penetration.
Opportunities abound in expanding patient qualification, market awareness, and operational efficiency, positioning Inspire for sustained growth and market leadership in the healthcare sector.

Inspire Medical Systems reports strong Q2 performance and growth outlook

Inspire Medical Systems demonstrated robust financial performance, marked by revenue growth and improved profitability.
Strategic initiatives to enhance patient experience and expand market reach position the company for sustained growth.
While facing challenges related to rising expenses, the company's focus on operational efficiency and growth opportunities remains strong.

Inspire Medical Systems reports strong Q3 earnings and growth outlook

Inspire Medical Systems Inc demonstrated robust financial performance in Q3 2024, with revenue and net income showing significant growth.
Despite challenges like revenue headwinds in Q4, the company's focus on innovation and capacity expansion presents growth opportunities.
The upcoming launch of the Inspire V system and efforts to streamline patient access highlight Inspire's commitment to driving future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inspire Medical Systems is radically transforming how we treat sleep apnea.

This Tiny Medical Device Will Make Billions of Dollars

MINNEAPOLIS, April 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2022 after the close of trading on Tuesday, May 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report First Quarter 2022 Financial Results on May 3, 2022

AstraZeneca

Vertex Pharmaceuticals

Many healthcare stocks have been outperforming the market averages this year. Here are three stocks our roundtable likes.

Don't Tell These 3 Healthcare Stocks There's a Bear Market

Inspire Medical Systems Inc INSP generated revenue of $78.39 million in Q4, a 70% Y/Y increase, marginally beating the consensus of $78.11 million and in line with the management expectation. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Inspire Medical Clocks 70% Increase In Q4 Sales, Issues FY22 Guidance Ahead Of Consensus

Inspire Medical Systems, Inc. (INSP) CEO Tim Herbert on Q4 2021 Results - Earnings Call Transcript

Inspire (INSP) delivered earnings and revenue surprises of 80.85% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q4 Loss, Tops Revenue Estimates

Accelerated Patient Demand and Increased Center Capacity Drives Year-over-Year Revenue Growth of 70% and 102% in the Fourth Quarter and Full Year, Respectively Accelerated Patient Demand and Increased Center Capacity Drives Year-over-Year Revenue Growth of 70% and 102% in the Fourth Quarter and Full Year, Respectively

Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance

Inspire Medical (INSP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Inspire Medical (INSP) Might Surprise This Earnings Season

MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022.

Inspire Medical Systems, Inc. to Present at the 11th Annual SVB Leerink Global Healthcare Conference

MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021 after the close of trading on Tuesday, February 8.   Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2021 Financial Results on February 8, 2022

Inspire Medical Systems Inc (NYSE: INSP) expects Q4 FY21 revenue of $78.0 million - $78.4 million, up approximately 70% Y/Y and surpassing the consensus estimate of $65.84 million. For FY21, the Company sees sales of $233.0 million - $233.4 million, an approximately 102% increase over FY20.

Inspire Medical Expects Strong Q4 FY21 Revenue Growth

MINNEAPOLIS, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Goldman Sachs Healthcare CEO Conference on Thursday, January 6, 2022.

Inspire Medical Systems, Inc. to Present at the Goldman Sachs Healthcare CEO Conference 2022

MINNEAPOLIS, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.

Inspire Medical Systems, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, is providing an update on the 2022 Reimbursement payment rates for Inspire procedures performed in Ambulatory Surgical Centers (ASCs).

Inspire Medical Systems, Inc. Provides Update on 2022 Ambulatory Surgical Center Reimbursement Levels

Inspire Medical Systems, Inc. (INSP) CEO Tim Herbert on Q3 2021 Results - Earnings Call Transcript

MINNEAPOLIS, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2021.

Inspire Medical Systems, Inc. Announces Third Quarter 2021 Financial Results and Updates 2021 Outlook

MINNEAPOLIS, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021.

Inspire Medical Systems, Inc. to Present at the Stifel 2021 Virtual Healthcare Conference

Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Inspire Medical Systems (INSP) to Report a Decline in Earnings: What to Look Out for

Omnicell

10X Genomics

Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.

Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges

Inspire Medical's unique product offering intends to disrupt a complex disease segment ruled by non-compliance on substitutes.

Inspire Medical: Long-Term Upside Imminent, Valuations Worrying

MINNEAPOLIS, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2021 after the close of trading on Tuesday, November 2. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Third Quarter 2021 Financial Results on November 2, 2021

MINNEAPOLIS, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, is dedicating the week of September 13, 2021, to its continued commitment to further advancing quality as a founding principle that has led to the company's success.

Inspire Medical Systems, Inc. Announces Quality Week and Launch of the Patient Experience Report

MINNEAPOLIS, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that a Centers for Medicare and Medicaid Services (CMS) panel has unanimously approved a recommendation to increase the previously proposed reimbursement for Inspire procedure performed in Ambulatory Surgical Centers (ASCs) as indicated on the CMS website as posted today.

Inspire Medical Systems, Inc. Announces Recommendation by Medicare Panel to Increase Payments for Inspire Therapy to Ambulatory Surgical Centers

MINNEAPOLIS, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 2021 Virtual Healthcare Conference on Thursday, September 9, 2021.

Inspire Medical Systems, Inc. to Present at the Wells Fargo 2021 Virtual Healthcare Conference

The stock price of Inspire Medical Systems Inc (NYSE: INSP) increased by over 10% pre-market. This is why it happened.

News for Inspire Medical Systems Inc Stock (INSP)